| Year |
Citation |
Score |
| 2020 |
Blaquiere N, Villemure E, Staben ST. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases. Journal of Medicinal Chemistry. PMID 32142281 DOI: 10.1021/Acs.Jmedchem.9B01451 |
0.303 |
|
| 2017 |
Schempp TT, Daniels BE, Staben ST, Stivala CE. A General Strategy for the Construction of Functionalized Azaindolines via Domino Palladium-Catalyzed Heck Cyclization/Suzuki Coupling. Organic Letters. PMID 28653542 DOI: 10.1021/Acs.Orglett.7B01606 |
0.498 |
|
| 2015 |
Gesinski MR, Brenzovich WE, Staben ST, Srinilta DJ, Toste FD. A divergent/convergent approach to dolabriferol: The Kornblum-DeLaMare enantiomeric resolution Tetrahedron Letters. DOI: 10.1016/J.Tetlet.2015.02.067 |
0.733 |
|
| 2013 |
Staben ST, Blaquiere N, Tsui V, Kolesnikov A, Do S, Bradley EK, Dotson J, Goldsmith R, Heffron TP, Lesnick J, Lewis C, Murray J, Nonomiya J, Olivero AG, Pang J, et al. Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase. Bioorganic & Medicinal Chemistry Letters. 23: 897-901. PMID 23265894 DOI: 10.1016/J.Bmcl.2012.10.121 |
0.356 |
|
| 2012 |
Gosselin F, Savage SJ, Blaquiere N, Staben ST. Heteroarylation of azine N-oxides. Organic Letters. 14: 862-5. PMID 22260711 DOI: 10.1021/Ol203388J |
0.325 |
|
| 2011 |
Castanedo GM, Seng PS, Blaquiere N, Trapp S, Staben ST. Rapid synthesis of 1,3,5-substituted 1,2,4-triazoles from carboxylic acids, amidines, and hydrazines. The Journal of Organic Chemistry. 76: 1177-9. PMID 21235245 DOI: 10.1021/Jo1023393 |
0.521 |
|
| 2011 |
Castanedo GM, Seng PS, Blaquiere N, Trapp S, Staben ST. Metal-Free Synthesis of 1,3,5-Trisubstituted 1,2,4-Triazoles Synfacts. 2011: 477-477. DOI: 10.1055/S-0030-1259845 |
0.383 |
|
| 2010 |
Staben ST, Blaquiere N. Four-component synthesis of fully substituted 1,2,4-triazoles. Angewandte Chemie (International Ed. in English). 49: 325-8. PMID 19998301 DOI: 10.1002/Anie.200905897 |
0.53 |
|
| 2009 |
Sethofer SG, Staben ST, Hung OY, Toste FD. Synthesis of Ventricosene Synfacts. 2009: 364-364. DOI: 10.1055/S-0028-1088094 |
0.807 |
|
| 2008 |
Sethofer SG, Staben ST, Hung OY, Toste FD. Au(I)-catalyzed ring expanding cycloisomerizations: total synthesis of ventricosene. Organic Letters. 10: 4315-8. PMID 18759435 DOI: 10.1021/Ol801760W |
0.773 |
|
| 2007 |
Toste F, Staben S, Kennedy-Smith J, Huang D, Corkey B, LaLonde R. Synthesis of (+)-Lycopladine A Synfacts. 2007: 0123-0123. DOI: 10.1055/S-2006-955762 |
0.742 |
|
| 2006 |
Staben ST, Linghu X, Toste FD. Enantioselective synthesis of gamma-hydroxyenones by chiral base-catalyzed Kornblum DeLaMare rearrangement. Journal of the American Chemical Society. 128: 12658-9. PMID 17002354 DOI: 10.1021/Ja065464X |
0.794 |
|
| 2006 |
Staben ST, Kennedy-Smith JJ, Huang D, Corkey BK, Lalonde RL, Toste FD. Gold(I)-catalyzed cyclizations of silyl enol ethers: application to the synthesis of (+)-lycopladine A. Angewandte Chemie (International Ed. in English). 45: 5991-4. PMID 16888820 DOI: 10.1002/Anie.200602035 |
0.748 |
|
| 2006 |
Toste F, Staben S, Linghu X. Organocatalytic Asymmetric Kornblum-DeLaMare Rearrangement Synfacts. 2006: 1175-1175. DOI: 10.1055/S-2006-949454 |
0.76 |
|
| 2005 |
Johansson MJ, Gorin DJ, Staben ST, Toste FD. Gold(I)-catalyzed stereoselective olefin cyclopropanation. Journal of the American Chemical Society. 127: 18002-3. PMID 16366541 DOI: 10.1021/Ja0552500 |
0.789 |
|
| 2005 |
Markham JP, Staben ST, Toste FD. Gold(I)-catalyzed ring expansion of cyclopropanols and cyclobutanols. Journal of the American Chemical Society. 127: 9708-9. PMID 15998074 DOI: 10.1021/Ja052831G |
0.674 |
|
| 2004 |
Staben ST, Kennedy-Smith JJ, Toste FD. Gold(I)-catalyzed 5-endo-dig carbocyclization of acetylenic dicarbonyl compounds. Angewandte Chemie (International Ed. in English). 43: 5350-2. PMID 15468061 DOI: 10.1002/Anie.200460844 |
0.782 |
|
| 2004 |
Kennedy-Smith JJ, Staben ST, Toste FD. Gold(I)-catalyzed Conia-ene reaction of beta-ketoesters with alkynes. Journal of the American Chemical Society. 126: 4526-7. PMID 15070364 DOI: 10.1021/Ja049487S |
0.764 |
|
| 2004 |
Vyvyan JR, Loitz C, Looper RE, Mattingly CS, Peterson EA, Staben ST. Synthesis of aromatic bisabolene natural products via palladium-catalyzed cross-couplings of organozinc reagents. The Journal of Organic Chemistry. 69: 2461-8. PMID 15049646 DOI: 10.1021/Jo035778S |
0.483 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Staben ST. Abstract DDT02-01: Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ddt02-01 |
0.279 |
|
| 2012 |
Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, ... ... Staben S, et al. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic & Medicinal Chemistry Letters. 22: 4296-302. PMID 22672799 DOI: 10.1016/J.Bmcl.2012.05.027 |
0.274 |
|
| 2013 |
Olivero AG, Heffron TP, Baumgardner M, Belvin M, Ross LB, Blaquiere N, Bradley E, Castanedo G, Derynck M, Do S, Dotson J, Dudley D, Edgar K, Folkes A, Francis R, ... ... Staben S, et al. Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Ddt02-01 |
0.271 |
|
| 2011 |
Heffron TP, Wei B, Olivero A, Staben ST, Tsui V, Do S, Dotson J, Folkes AJ, Goldsmith P, Goldsmith R, Gunzner J, Lesnick J, Lewis C, Mathieu S, Nonomiya J, et al. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform. Journal of Medicinal Chemistry. 54: 7815-33. PMID 21985639 DOI: 10.1021/Jm2007084 |
0.266 |
|
| 2019 |
Feng JA, Lee P, Alaoui MH, Barrett K, Castanedo G, Godemann R, McEwan P, Wang X, Wu P, Zhang Y, Harris SF, Staben ST. Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1). Acs Medicinal Chemistry Letters. 10: 1260-1265. PMID 31531194 DOI: 10.1021/Acsmedchemlett.8B00658 |
0.266 |
|
| 2017 |
Safina BS, Elliott RL, Forrest AK, Heald RA, Murray JM, Nonomiya J, Pang J, Salphati L, Seward EM, Staben ST, Ultsch M, Wei B, Yang W, Sutherlin DP. Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. Acs Medicinal Chemistry Letters. 8: 936-940. PMID 28947940 DOI: 10.1021/Acsmedchemlett.7B00170 |
0.265 |
|
| 2018 |
Blaquiere N, Castanedo G, Burch J, Berezhkovskiy L, Brightbill H, Brown S, Chan C, Chiang PC, Crawford JJ, Dong T, Fan P, Feng J, Ghilardi N, Godemann R, Gogol E, ... ... Staben ST, et al. A scaffold-hopping approach to discover potent, selective and efficacious inhibitors of NF-κB inducing kinase. Journal of Medicinal Chemistry. PMID 29940120 DOI: 10.1021/Acs.Jmedchem.8B00678 |
0.264 |
|
| 2013 |
Staben ST, Ndubaku C, Blaquiere N, Belvin M, Bull RJ, Dudley D, Edgar K, Gray D, Heald R, Heffron TP, Jones GE, Jones M, Kolesnikov A, Lee L, Lesnick J, et al. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform. Bioorganic & Medicinal Chemistry Letters. 23: 2606-13. PMID 23540645 DOI: 10.1016/J.Bmcl.2013.02.102 |
0.263 |
|
| 2019 |
Dragovich PS, Adhikari P, Blake RA, Blaquiere N, Chen J, Cheng YX, den Besten W, Han J, Hartman SJ, He J, He M, Rei Ingalla E, Kamath AV, Kleinheinz T, Lai T, ... ... Staben ST, et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorganic & Medicinal Chemistry Letters. 126907. PMID 31902710 DOI: 10.1016/J.Bmcl.2019.126907 |
0.261 |
|
| 2017 |
Edgar K, Hanan E, Staben S, Schmidt S, Hong R, Song K, Young A, Hamilton P, Arrazate A, Cruz Cdl, Belvin M, Nannini M, Friedman LS, Sampath D. Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development Cancer Research. 77: 156-156. DOI: 10.1158/1538-7445.Am2017-156 |
0.256 |
|
| 2016 |
Heffron TP, Heald RA, Ndubaku CO, Wei B, Augustin M, Do S, Edgar K, Eigenbrot C, Lori F, Gancia E, Jackson P, Jones G, Kolesnikov A, Lee L, Lesnick J, ... ... Staben ST, et al. The Rational Design of Selective Benzoxazepin Inhibitors of the -Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). Journal of Medicinal Chemistry. PMID 26741947 DOI: 10.1021/Acs.Jmedchem.5B01483 |
0.25 |
|
| 2014 |
Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua CC, Cui H, DiPasquale AG, Friedman LS, Heise C, Koeppen H, Kotey A, Mintzer R, Oh A, et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. Journal of Medicinal Chemistry. 57: 1033-45. PMID 24432870 DOI: 10.1021/Jm401768T |
0.248 |
|
| 2016 |
Castanedo GM, Blaquiere N, Beresini MH, Bravo B, Brightbill H, Chen J, Cui H, Eigenbrot C, Everett C, Feng JA, Godemann R, Gogol E, Hymowitz SG, Johnson AR, Kayagaki N, ... ... Staben ST, et al. Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K). Journal of Medicinal Chemistry. PMID 28005357 DOI: 10.1021/Acs.Jmedchem.6B01363 |
0.247 |
|
| 2010 |
Staben ST, Heffron TP, Sutherlin DP, Bhat SR, Castanedo GM, Chuckowree IS, Dotson J, Folkes AJ, Friedman LS, Lee L, Lesnick J, Lewis C, Murray JM, Nonomiya J, Olivero AG, et al. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase. Bioorganic & Medicinal Chemistry Letters. 20: 6048-51. PMID 20822905 DOI: 10.1016/J.Bmcl.2010.08.067 |
0.233 |
|
| 2011 |
Staben ST, Siu M, Goldsmith R, Olivero AG, Do S, Burdick DJ, Heffron TP, Dotson J, Sutherlin DP, Zhu BY, Tsui V, Le H, Lee L, Lesnick J, Lewis C, et al. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase. Bioorganic & Medicinal Chemistry Letters. 21: 4054-8. PMID 21636270 DOI: 10.1016/J.Bmcl.2011.04.124 |
0.231 |
|
| 2013 |
Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. Journal of Medicinal Chemistry. 56: 4597-610. PMID 23662903 DOI: 10.1021/Jm4003632 |
0.228 |
|
| 2018 |
Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, Lesch J, Bents K, Everett C, Kohli PB, Linge S, ... ... Staben ST, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nature Communications. 9: 179. PMID 29330524 DOI: 10.1038/S41467-017-02672-0 |
0.226 |
|
| 2019 |
Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PHV, Šimon P, Šubrt V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, et al. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. Plos Biology. 17: e3000354. PMID 31525186 DOI: 10.1371/Journal.Pbio.3000354 |
0.221 |
|
| 2019 |
Ladi E, Everett C, Stivala CE, Daniels BE, Durk MR, Harris SF, Huestis M, Purkey HE, Staben ST, Augustin M, Blaesse M, Steinbacher S, Eidenschenk C, Pappu R, Siu M. Design and Evaluation of Highly-Selective Human Immunoproteasome Inhibitors Reveals a Compensatory Process that Preserves Immune Cell Viability. Journal of Medicinal Chemistry. PMID 31283222 DOI: 10.1021/Acs.Jmedchem.9B00509 |
0.221 |
|
| 2020 |
Hanan EJ, Liang J, Wang X, Blake R, Blaquiere N, Staben ST. Monomeric targeted protein degraders. Journal of Medicinal Chemistry. PMID 32352776 DOI: 10.1021/Acs.Jmedchem.0C00093 |
0.221 |
|
| 2019 |
Yamazoe S, Tom J, Fu Y, Wu W, Zeng L, Sun C, Liu Q, Lin J, Lin K, Fairbrother WJ, Staben ST. Heterobifunctional molecules induce dephosphorylation of kinases - a proof of concept study. Journal of Medicinal Chemistry. PMID 31874036 DOI: 10.1021/Acs.Jmedchem.9B01167 |
0.219 |
|
| 2013 |
Hoeflich K, Ong C, Lyle K, Jubb A, Zhou W, Harris A, Belvin M, Friedman L, Koeppen H, Rudolph J, Staben S. Abstract A067: Targeting p21-activated kinases in breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A067 |
0.214 |
|
| 2012 |
de Leon-Boenig G, Bowman KK, Feng JA, Crawford T, Everett C, Franke Y, Oh A, Stanley M, Staben ST, Starovasnik MA, Wallweber HJ, Wu J, Wu LC, Johnson AR, Hymowitz SG. The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure (London, England : 1993). 20: 1704-14. PMID 22921830 DOI: 10.1016/J.Str.2012.07.013 |
0.211 |
|
| 2022 |
McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, Veal J, Takahashi R, Ly J, Chen S, Liu L, ... ... Staben ST, et al. Overcoming Preclinical Safety Obstacles to Discover ()--((1,2,3,5,6,7-Hexahydro--indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5-pyrazolo[5,1-][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. Journal of Medicinal Chemistry. PMID 36279149 DOI: 10.1021/acs.jmedchem.2c01250 |
0.137 |
|
| 2022 |
Hanan EJ, Braun MG, Heald RA, MacLeod C, Chan C, Clausen S, Edgar KA, Eigenbrot C, Elliott R, Endres N, Friedman LS, Gogol E, Gu XH, Thibodeau RH, Jackson PS, ... ... Staben ST, et al. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. Journal of Medicinal Chemistry. PMID 36455032 DOI: 10.1021/acs.jmedchem.2c01422 |
0.114 |
|
| 2021 |
Besten WD, Verma K, Yamazoe S, Blaquiere N, Phung W, Izrael-Tomasevic A, Mulvihill MM, Helgason E, Prakash S, Goncharov T, Vucic D, Dueber E, Fairbrother WJ, Wertz I, Yu K, ... Staben ST, et al. Primary Amine Tethered Small Molecules Promote the Degradation of X-Linked Inhibitor of Apoptosis Protein. Journal of the American Chemical Society. PMID 34236858 DOI: 10.1021/jacs.1c05269 |
0.111 |
|
| 2021 |
Hu DX, Patel S, Chen H, Wang S, Staben ST, Dimitrova YN, Wallweber HA, Lee JY, Chan GKY, Sneeringer CJ, Prangley MS, Moffat JG, Wu KC, Schutt LK, Salphati L, et al. Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 34779204 DOI: 10.1021/acs.jmedchem.1c01180 |
0.11 |
|
| 2023 |
Crawford JJ, Feng J, Brightbill HD, Johnson AR, Wright M, Kolesnikov A, Lee W, Castanedo GM, Do S, Blaquiere N, Staben ST, Chiang PC, Fan PW, Baumgardner M, Wong S, et al. Filling a nick in NIK: extending the half-life of a NIK inhibitor through structure-based drug design. Bioorganic & Medicinal Chemistry Letters. 129277. PMID 37105490 DOI: 10.1016/j.bmcl.2023.129277 |
0.11 |
|
| 2022 |
Bashore C, Prakash S, Johnson MC, Conrad RJ, Kekessie IA, Scales SJ, Ishisoko N, Kleinheinz T, Liu PS, Popovych N, Wecksler AT, Zhou L, Tam C, Zilberleyb I, Srinivasan R, ... ... Staben ST, et al. Targeted degradation via direct 26S proteasome recruitment. Nature Chemical Biology. 19: 55-63. PMID 36577875 DOI: 10.1038/s41589-022-01218-w |
0.109 |
|
| 2022 |
Steffek M, Helgason E, Popovych N, Rougé L, Bruning JM, Li KS, Burdick DJ, Cai J, Crawford T, Xue J, Decurtins W, Fang C, Grubers F, Holliday MJ, Langley A, ... ... Staben ST, et al. A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands. Biochemistry. PMID 34985287 DOI: 10.1021/acs.biochem.1c00682 |
0.103 |
|
| 2021 |
Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, Sampath D, Nannini MA, Hong R, Phu L, Forrest WF, Stawiski E, Schmidt S, Endres N, Guan J, ... ... Staben ST, et al. RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy. Cancer Discovery. PMID 34544753 DOI: 10.1158/2159-8290.CD-21-0072 |
0.088 |
|
| 2023 |
Rosenberg SC, Shanahan F, Yamazoe S, Kschonsak M, Zeng YJ, Lee J, Plise E, Yen I, Rose CM, Quinn JG, Gazzard LJ, Walters BT, Kirkpatrick DS, Staben ST, Foster SA, et al. Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. Cell Chemical Biology. PMID 36773603 DOI: 10.1016/j.chembiol.2023.01.007 |
0.082 |
|
| 2021 |
Dragovich PS, Pillow TH, Blake RA, Sadowsky JD, Adaligil E, Adhikari P, Bhakta S, Blaquiere N, Chen J, Dela Cruz-Chuh J, Gascoigne KE, Hartman SJ, He M, Kaufman S, Kleinheinz T, ... ... Staben ST, et al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties. Journal of Medicinal Chemistry. PMID 33596065 DOI: 10.1021/acs.jmedchem.0c01845 |
0.078 |
|
| 2021 |
Chang MT, Shanahan F, Nguyen TTT, Staben ST, Gazzard L, Yamazoe S, Wertz IE, Piskol R, Yang YA, Modrusan Z, Haley B, Evangelista M, Malek S, Foster SA, Ye X. Identifying transcriptional programs underlying cancer drug response with TraCe-seq. Nature Biotechnology. PMID 34531539 DOI: 10.1038/s41587-021-01005-3 |
0.051 |
|
| 2012 |
Gosselin F, Savage SJ, Blaquiere N, Staben ST. ChemInform Abstract: Heteroarylation of Azine N-Oxides. Cheminform. 43: no-no. DOI: 10.1002/chin.201224144 |
0.051 |
|
| 2019 |
Walle LV, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PHV, Šimon P, Šubr V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, et al. Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. Plos Biology. 17: e3000529. PMID 31618263 DOI: 10.1371/journal.pbio.3000529 |
0.04 |
|
| 2021 |
Amara N, Cooper MP, Voronkova MA, Webb BA, Lynch EM, Kollman JM, Ma T, Yu K, Lai Z, Sangaraju D, Kayagaki N, Newton K, Bogyo M, Staben ST, Dixit VM. Selective activation of PFKL suppresses the phagocytic oxidative burst. Cell. PMID 34320407 DOI: 10.1016/j.cell.2021.07.004 |
0.04 |
|
| Hide low-probability matches. |